Nervous system growth factors have extensive effects on neuronal function and survival. Nerve Growth Factor (NGF) prevents the death and stimulates the function of basal forebrain cholinergic neurons in correlational models of Alzheimer's disease (AD), leading to its translation to Phase 1 and 2 human clinical trials. Separately, Brain-Derived Neurotrophic Factor (BDNF) infl uences the survival and function of entorhinal cortical and hippocampal neurons in several animal models of AD, including transgenic mutant APP-expressing mice, aged and lesioned rats, and aged and lesioned primates. These benefi cial effects occur independent of detectable alterations in beta amyloid load. We are currently examining the extended safety and tolerability of BDNF gene delivery to the entorhinal cortex in animal studies, leading to specifi c targeting of short-term memory loss in upcoming human AD trials. Collectively, a large body of research suggests that growth factor therapy represents an alternative to amyloid-modifying drugs for preventing neuronal degeneration and stimulating neuronal function in Alzheimer's disease, with the potential to reduce disease progression.
Introduction
Gene therapy is a developing technology that has the potential to treat a number of human diseases, including neurodegenerative disorders. Gene therapy allows the expression of specifi c proteins in defi ned types of cells with anatomical specifi city in the central nervous system; this approach might be useful for the treatment of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and others. The most prevalent neurodegenerative disorder is Alzheimer's disease (AD), currently affl icting about 36 million people worldwide. Existing treatments for AD are only marginally effective and fail to infl uence disease progression. Treatment approaches to AD that target modulation of beta amyloid production are undergoing advanced clinical testing, but these drugs have to date not altered the course of established disease, leading to current efforts to treat AD before symptom onset. Thus, alternative approaches to therapy are needed: growth factor gene therapy exhibits effi cacy in AD animal models when treatment is begun after disease onset. Moreover, by targeting a mechanism other than amyloid, growth factor gene therapy offers the potential of combination therapy with amyloid-modifying drugs. This chapter reviews the use of gene therapy with neurotrophic factors in the treatment of this complex disorder.
Alzheimer's Disease

Background
Alois Alzheimer, a German psychiatrist and neuropathologist, fi rst described AD in 1906. It is now the most prevalent neurodegenerative disease. Five million people in the United States are currently affected by AD, and an estimated 36 million people are affected worldwide. The age of AD onset is past 65 years of age in 95 % of cases [ 1 ] . With the expansion of the aged population, the number of AD victims is predicted to be 13.8 million people in the United States and 115 million people worldwide by 2050 [ 1 , 2 ] . Annual estimated costs of AD care in the United States alone are estimated over $200 billion, not including the cost of care provided by family members [ 1 ] . Unfortunately, there are no substantially effective therapies either to improve AD symptoms or to slow progression of the disease. While cholinesterase inhibitors and the drug memantine (Namenda; a putative glutamate antagonist) yield detectable symptomatic benefi ts, the overall impact of these drugs is small [ 3 -5 ] . Better therapies are clearly needed in general, and the development of disease-modifying drugs in particular remains an important goal of the fi eld.
Symptoms and Neuropathology
Short-term memory loss is the cardinal symptom of AD, and may occur in isolation in the earliest symptomatic stages of the disease. As the disease progresses, other cognitive domains become impaired including executive function, visuospatial skills, language, perceptual processing, and attention [ 6 ] . Behavioral dysfunction can also occur, including aggression, agitation, psychosis, and motor dysfunction [ 7 ] . Diagnosis of AD currently rests primarily on cognitive testing. However, a major focus of research is the development of biomarkers of AD at its earliest stages, including presymptomatic states. Recent evidence indicates that changes in the brain can be visualized by PET imaging of amyloid plaques [ 8 ] and possibly tau [ 9 ] , hippocampal atrophy on quantitative MRI [ 10 ] , and changes in cerebrospinal fl uid and blood biomarkers [ 1 , 11 -13 ] . However, the current diagnosis of AD in clinical practice still rests on predominantly clinical measures, and is typically made at a stage in which patients already exhibit short-term memory loss; at this stage of the disease, there is already substantial damage to the entorhinal-hippocampal region [ 14 -17 ] .
Neuropathological features of AD in the brain consist of hallmark features of amyloid plaque formation and intraneuronal neurofi brillary degeneration ( Fig. 3.1 ). With this, there are a loss of synapses and then neurons. These neuropathological features are found in many regions of the brain at later stages of the disease. However, the initial neuropathology starts in the entorhinal cortex and hippocampus, spreading to other brain regions [ 18 -20 ] . The abnormal processing and subsequent accumulation of beta amyloid peptide constitutes one essential component of pathological degeneration [ 21 ] . Approximately 5 % of AD cases represent an earlyonset familial form of the disease related to mutations of either the amyloid precursor protein gene itself or presenilin genes that result in accumulation of beta amyloid in the brain [ 22 ] . Neurofi brillary tangles consist of accumulations of hyperphosphorylated Tau protein in neurons [ 23 ] . Accumulation of Tau is an essential feature of a diagnosis of AD, and Tau accumulation is also found in other neurodegenerative disorders including frontotemporal dementia and multisystem atrophies [ 24 ] .
The loss of synaptic connections represents a major neuropathological feature of AD that occurs early in the disease process and is most directly associated with cognitive decline [ 25 ] . Synapse loss also correlates eventually with the extent of beta amyloid accumulation [ 26 , 27 ] . Alzheimer's disease is further associated with ( a ) Amyloid deposition in the hippocampus of a typical AD patient. Inset illustrates the presence of dense-core and diffuse plaques. ( b ) Neurofi brillary tangles in the hippocampus of an AD patient. Inset shows neurofi brillary tangles and dense tau pathology a loss of neurotrophic factor levels or availability in the brain [ 28 -31 ] , which in turn directly infl uences synaptic function [ 32 , 33 ] . The loss of synaptic connections may be critical, since the loss is highly correlated to functional decline in AD [ 27 , 34 ] . A number of secondary pathological changes also occur in AD including infl ammation, mitochondrial dysfunction, increased oxidative stress, dysregulation of cellular calcium homeostasis, and axonal transport defects [ 29 , 35 -37 ] .
The progressive nature of cognitive decline in AD refl ects the ongoing neuropathology in localized brain regions [ 18 , 19 ] . The entorhinal cortex is the fi rst brain region to undergo neurodegeneration in initial stages of AD [ 18 , 19 ] . Early memory defi cits in AD are thought to refl ect this entorhinal and hippocampal pathology, as indicated by loss of cells [ 14 , 16 ] and synaptics between the entorhinal cortex and hippocampus [ 34 , 38 ] . Volumetric studies using MRI confi rm early changes in the entorhinal cortex and hippocampus in the mild cognitive impairment stage of AD [ 39 -42 ] . As the disease advances, neuropathology progresses to other cortical areas and limbic structures. The progression of AD to other brain regions represents patterns of anatomical connectivity [ 20 , 43 , 44 ] . Recent evidence indicates that patterns of anatomical spread might be related to trans-neuronal spread of tau proteins [ 45 , 46 ] . Thus, slowing the progression of AD in the brain regions affected during the early stages might represent an effective treatment strategy. This is an objective of the BDNF gene therapy program in AD, as described below.
Numerous other brain regions are also damaged in AD. The basal forebrain cholinergic system is among these and may have particular importance [ 47 , 48 ] . Cholinergic neurons of the basal forebrain regulate neural activity in the hippocampus, neocortex, and other cortical regions and exert an important role in attention and memory function [ 49 , 50 ] . Indeed, one of only two classes of drugs approved for the treatment of AD compensates for cholinergic degeneration by inhibiting cholinesterase activity and elevating acetylcholine levels [ 3 , 51 ] . However, the efficacy of this class of drugs is relatively mild, in part due to dose-limiting side affects resulting from nonspecifi c activation of cholinergic activity systemically, rather than a focused effect on active cortical systems. Hypothetically, a therapy that preserves cholinergic neurons could represent a superior therapy in AD: this is the objective of the nerve growth factor (NGF) gene therapy program in AD, described below.
The only other class of drug approved for the treatment of AD in the United States is the partial NMDA antagonist memantine (Namenda) [ 5 ] . Memantine, like cholinesterase inhibitors, targets diverse neurons throughout the brain. However, the overall impact of this drug on clinical symptoms is also relatively mild, and memantine does not change disease progression [ 51 ] .
Several clinical trials are now in progress that aim to reduce beta amyloid accumulation in the brain and accordingly reduce AD progression. Data in amyloidogenic mouse models heralded this line of work [ 52 ] . Amyloid precursor protein is a transmembrane protein that can be cleaved by beta-and gamma-secretases, resulting in accummulation of "mature" beta amyloid fragments of 40-42 amino acids together with the activation of intracellular caspace activity. To reduce cleavage of amyloid precursor protein and reduce beta amyloid accumulation, secretases can be inhibited or modulated [ 51 ] (see Chap. 19 ) . Alpha secretases also cleave amyloid precursor protein to produce a non-amyloidogenic peptide, and drugs aimed at increasing alpha secretase activity represent another therapeutic strategy. Clinical trials with these drugs in AD patients to date have been disappointing, but work is ongoing with modifi ed versions of the drugs and in patients with earlier stage or even presymptomatic AD.
Another way to target beta amyloid pathology in AD is to clear it from the brain. So-called immunotherapy can either generate an immune response to beta amyloid or infuse antibodies directed against beta amyloid to enhance its removal from the brain [ 51 ] . The fi rst such clinical trial in AD was performed in 2002 and actively immunized patients with the 42 amino acid Aβ1-42 peptide, together with an immune adjuvant to stimulate antibody production [ 53 -55 ] . 6 % of vaccinated AD patients developed an apparent autoimmune meningoencephalitis, resulting in a halt to the trial [ 53 , 56 ] . However, patients who generated an anti-Aβ antibody response showed reduced levels of tau in the CSF [ 53 , 57 ] . The brains of a small cohort of patients from the trial demonstrated a signifi cant reduction in amyloid plaques in the brain compared to non-treated controls, but disappointingly showed no evident cognitive benefi t [ 54 ] . Current clinical trials in AD are excluding immune adjuvants when administering immunizing peptides, are using different immunizing peptides, or are directly infusing monoclonal antibodies directed against Aβ (passive immunization). Two clinical trials of Aβ monoclonal antibody therapy (bapineuzumab and solanezumab) failed to achieve statistically signifi cant clinical benefi ts on preplanned primary outcome measures [ 56 ] , but raised the possibility of potential benefi t in patients with more mild disease. Given the apparently pivotal role of beta amyloid in the pathogenesis of AD, and the potential signal of benefi t of antiamyloid therapy in patients with milder disease, the hypothesis has been raised that treatment may have to begin at very early stages of the disease, perhaps even in patients at risk for AD who have not yet developed clinical symptoms. Indeed, since subsequent clinical trials of anti-amyloid therapies have generally shown good safety, several large clinical trials in presymptomatic patients with familial AD or high amyloid plaque load have begun [ 54 ] . These are very important studies.
Additional drugs are undergoing testing in AD clinical trials, targeting other components of neuropathology. Beta amyloid toxicity may occur in part as a result of aggregation of Aβ oligomers [ 58 ] , and drugs that prevent oligomer aggregation are being tested. Tau proteins are another intriguing target for AD clinical trials, given their pivotal role also in AD pathology. Anti-tau treatments aim to reduce formation of intraneuronal neurofi brillary tangles or to reduce tau phosphorylation. More recently, following the example of immunotherapy directed against beta amyloid, anti-Tau antibodies have begun clinical testing in AD [ 59 ] . Anti-infl ammatory treatment has also been investigated as a potential therapy for the treatment of AD, since infl ammation occurs at sites of amyloid plaque deposition that may contribute to neuropathology in AD. To date, results of these trials have been disappointing [ 60 , 61 ] , but interest in anti-infl ammatory approaches persists [ 62 ] .
Gene-based therapies are another important component in the attempt to identify new therapies for AD. As described in the following sections, gene therapy has the potential to target degenerating neuronal systems of the brain specifi cally, over long time periods, and with novel and biologically potent agents such as nervous system growth factors. As a class, neuronal growth factors stimulate the functional state of neurons, preserve and rebuild synapses, and prevent neuronal death.
AD Gene Therapy
Gene therapy approaches have been reported in a number of preclinical models of AD (e.g., [ 63 -81 ] ). Several of these studies report benefi cial effects of a candidate gene on AD-related pathology and cognitive performance. One of these approaches, NGF gene therapy, has undergone three clinical trials in AD, including two Phase 1 and a current Phase 2 study. NGF gene therapy in AD was in fact the fi rst trial of gene therapy in the adult nervous system for any neurodegenerative indication. The rationale and current state of this program are described below.
NGF Gene Therapy for Alzheimer's Disease
Discovery and Effects of NGF
Nerve Growth Factor (NGF) was discovered in the 1950s by Rita Levi-Montalcini and Viktor Hamburger. It is one member of the "neurotrophin" family that includes BDNF, neurotrophin-3 (NT-3), and neutrotrophin-4/5 (NT-4/5), molecules that are structurally related. NGF was discovered serendipitously when it unexpectedly elicited exuberant outgrowth of neurites when cocultured with mouse sarcoma cells, and was subsequently identifi ed as an essential factor for the survival and development of peripheral sensory and sympathetic neurons [ 82 , 83 ] . Its potential role in nervous system degeneration was not appreciated until nearly 35 years later, when groundbreaking studies demonstrated that NGF prevents the death of adult basal forebrain cholinergic neurons in rats after injury [ 84 -86 ] (Fig. 3.2 ). Shortly thereafter, NGF was also shown to reverse age-related atrophy of basal forebrain cholinergic neurons in rats [ 87 -89 ] . Extending these fi ndings, NGF also reduced cholinergic neuronal atrophy in a mouse model of Down's syndrome (trisomy 16), wherein an extra copy of the amyloid precursor protein gene is associated with cholinergic degeneration, and improved cognition [ 90 , 91 ] . Subsequent work extended these fi ndings to the [ 79 ] . Scale bar 250 μm brains of adult lesioned nonhuman primates, and to aged monkeys that exhibit spontaneous, age-related atrophy of cholinergic neurons [ 65 , 72 , 92 -94 ] (Fig. 3.3 ). Furthermore, NGF prevented neuronal degeneration caused by excitotoxic lesions of basal forebrain cholinergic neurons or by cortical lesions in rats [ 95 , 96 ] .
There is a clear rationale for targeting NGF-responsive basal forebrain cholinergic neurons for treatment in AD. Basal forebrain cholinergic neurons of the medial septal nucleus and nucleus basalis of Meynert (NBM) project to neurons throughout hippocampus and neocortex, and modulate neuronal activity. These systems infl uence attention, memory, and cortical executive functions, and are required for certain complex forms of learning [ 50 , 97 -101 ] . These cholinergic neurons degenerate early in AD [ 47 , 48 , 102 , 103 ] likely contributing to symptom development in early and mid-stage AD. Cholinesterase inhibitors partially compensate for reductions in cholinergic systems in AD, demonstrating effi cacy in multiple clinical trials in AD [ 51 ] . However, these drugs act broadly across brain synapses rather than in a synapse-and time-specifi c manner that mimics physiological acetylcholine release. Hypothetically, therapies that reduce cholinergic degeneration and sustain normal cholinergic cell function in AD could represent a considerable advance over the use of cholinesterase drugs. Furthermore, dosing of cholinesterase inhibitor drugs in AD is limited by peripheral side effects. While other neuronal systems also degenerate in early AD, the loss of cholinergic neurons represents an important component of the neuropathology. Whether targeting this neuronal system alone will be suffi cient to slow cognitive decline remains an open question, and a question that the clinical program aims to address.
Thus, basal forebrain cholinergic neurons undergo degeneration in AD and may contribute to characteristic symptoms of the disease. Importantly, these neurons are highly sensitive to NGF, and NGF treatment could represent a means of slowing cholinergic neuronal degeneration in AD. NGF is normally synthesized by cortical and hippocampal neurons, and its availability throughout life sustains cholinergic inputs to these brain regions. Cholinergic axon terminals in the hippocampus and cortex take up the secreted NGF, and retrogradely transport it back to cholinergic cell bodies in the medial septal nucleus and nucleus basalis of Meynert [ 29 ] . Upon entry into the cholinergic cell soma, NGF activates the acetylcholine (ACh) synthesizing enzyme, choline acetyltransferase (ChAT), and the vesicular acetylcholine transporter (VAChT) [ 103 , 105 ] . In AD, NGF levels decline in the basal forebrain while they build up in the cortex, suggesting a retrograde transport defect of NGF to the basal forebrain [ 29 , 31 , 106 ] . The cause of this transport defect is unknown, but could result from alterations in cellular machinery for axonal transport, neuroskeletal instability related to Tau, or perturbations resulting from amyloid precursor protein processing [ 107 ] . In theory, NGF directly applied to the cholinergic cell somata in the nucleus basalis of Meynert could bypass NGF transport defi cits to sustain and functionally activate [ 108 ] the neurons in AD. Receptors for NGF are expressed on both cholinergic axons and cell bodies.
The preceding considerations led to an effort to treat AD patients with NGF protein infusions approximately 20 years ago [ 108 ] . Because NGF is a medium-sized, moderately polar molecule that does not cross the blood-brain barrier, early animal studies infused it into the lateral ventricles of the brain [ 84 , 86 , 109 ] . This route of administration succeeded in preventing cholinergic neuronal death and stimulating cell function, but it also broadly spread NGF through the cerebrospinal fl uid. As a result, several off-target effects occurred in animal models, including weight loss, sensory (nociceptive) and sympathetic axon sprouting that caused pain-related behaviors, and proliferation of Schwann cells around the medulla and spinal cortex [ 110 -113 ] . Of three AD patients who received NGF protein infusions into the cerebral ventricles, all three reported dull and constant back pain and two exhibited weight loss during NGF infusion [ 108 ] . Thus, despite the potential promise of NGF therapy in AD, these side effects required the development of new and better targeted means of NGF administration.
NGF Gene Therapy: Phase I Ex Vivo Clinical Trial
Following the initial failure of protein intracerebroventricular infusions, methods for delivering NGF were sought that could provide adequate protein concentrations in targeted brain regions (the nucleus basalis of Meynert) to prevent cholinergic neuronal degeneration, while restricting NGF distribution solely to this brain region to avoid off-target adverse effects. A potential solution to this problem was gene therapy. The physical size of the nucleus basalis of Meynert in humans is approximately 1 cm in length, and targeting this structure could impact cholinergic axon terminals throughout the cortex. Thus, the nucleus basalis of Meynert seemed a practical target that could be accessed in humans by neurosurgeons, using methods of gene delivery.
The brain consists nearly exclusively of nondividing cells, and at the time that the fi rst efforts were being made to translate NGF gene therapy to humans in the 1990s, gene therapy vectors for targeting nondividing cells of the brain were unsatisfactory. Adeno-associated viral vectors were not yet in extensive clinical use, and adenoviral vectors expressed wild-type genes that could generate immune responses. Thus, we pursued ex vivo gene transfer methods for NGF gene delivery in AD. Patient autologous fi broblasts were genetically modifi ed to produce and secrete human NGF using Moloney leukemia virus (MLV) retroviruses containing the relatively robust LTR (long terminal repeat) promoter. In preclinical experiments in rats and primates, this delivery method was found to deliver NGF to the basal forebrain cholinergic nuclei without extensive spread to other brain regions [ 65 , 73 , 77 , 80 ] . Moreover, ex vivo NGF gene delivery was effective in signifi cantly reducing lesioninduced cholinergic neuronal degeneration in both rodents and primates [ 65 , 73 , 77 , 80 ] . Importantly, NGF did not detectably spread to other brain regions, and the off-target effects of intracerebroventricular NGF protein infusions did not occur. Demonstrations of NGF effi cacy after gene transfer were extended to studies in aged rats, where age-related cholinergic cell atrophy was reversed and cognitive function improved [ 114 ] . Further studies in aged monkeys, performed in a manner to mimic potential human clinical trials, demonstrated that autologous fi broblasts expressing NGF reversed age-related neuronal atrophy restored cholinergic axon numbers in the neocortex [ 115 , 116 ] . Expression of NGF persisted for at least 1 year. Dose escalation and safety-toxicity studies demonstrated no adverse effects in monkeys. Taken together, these preclinical experiments indicated that ex vivo NGF gene therapy could accurately deliver NGF to the basal forebrain without eliciting adverse effects. Accordingly, the program advanced to human clinical trials.
The fi rst human trial of gene therapy in an adult neurodegenerative disorder began in 2001. Eight patients with early-stage AD were enrolled into a Phase 1 trial of ex vivo NGF gene therapy [ 117 ] . This clinical program aimed, through this initial and subsequent phase trials, to test the hypothesis that NGF could reduce cholinergic neuronal degeneration and stimulate neuronal function in AD, thereby detectably modifying disease progression. This fi rst phase 1 trial had more modest objectives, aiming to determine whether NGF gene delivery could be accomplished safely in AD patients. Primary autologous fi broblasts were taken by skin biopsies from each patient and expanded in a good manufacturing process (GMP) facility. They were then transduced with Moloney murine leukemia virus (MLV) vectors to express recombinant human full-length NGF. The NGF gene therapy vector included the pre-pro form of the NGF coding sequence and allowed packing of NGF into Golgi apparatus and subsequent secretion from the cell. Indeed, high levels of NGF were produced, generally on the order of 100 ng/10 6 cells/day, and most (99 %) of this NGF was secreted from the fi broblasts into the cell culture medium, providing a means of "bathing" the local cellular environment with NGF. In the adult brain, most NGF secreted from cells undergoes proteolytic cleavage to its active, prosurvival form; however, NGF can also exist extracellularly in its pro-form, which can promote cellular apoptosis [ 118 ] . NGF secreted from our transduced fi broblasts was nearly entirely the proteolytically cleaved, mature form of NGF, lacking pro-NGF. Clinical stereotaxic frames were used to implant patients' NGF-secreting autologous cells adjacent to the cholinergic basal forebrain. The fi rst two patients received implants of NGF-secreting cells solely into the right side of the brain, and the subsequent six patients received bilateral cell implantations. A range of cell "doses" (total numbers) was administered, from 1.25 million cells implanted unilaterally to 5 million cells implanted bilaterally.
Subjects were monitored posttreatment for the remainder of life. Adverse effects of NGF expression in the brain were not detected: pain, weight loss, or Schwann cell migration did not occur. An intraparenchymal hemorrhage occurred in one patient during the NGF gene transfer procedure that contributed to the patient's death approximately 1 month later. The future risk of this complication was addressed by modifying the design of the brain injection needle, and in 60 patients subsequently treated in phase 1 and phase 2 clinical trials, no additional hemorrhages have been reported.
Statements regarding effi cacy could not be made from the fi rst phase 1 ex vivo NGF gene therapy safety trial because only eight patients were enrolled, there was no control group, and blinded assessments could not be made. But cognitive function was measured serially over time and compared to preoperative baselines on the Mini-Mental Status Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive component (ADAS-Cog) [ 117 ] . Cognitive testing performed over a 2-year period following gene transfer showed an approximate 50 % reduction in the rate of cognitive decline after gene transfer compared to testing performed prior to the surgery. However, no conclusions regarding effi cacy could or should be drawn from these data given the small sample size, lack of control group, and non-blinded nature of data collection. One could reasonably conclude that, in this small set of patients, gene transfer did not appear to cause a worsening of cognitive function. Four bilaterally treated subjects who underwent NGF gene transfer were also examined by serial PET scans prior to and after treatment. Comparing post-to pretreatment 18-Fluorodeoxyglucose uptake, a signifi cant ( P < 0.05) increase in cortical uptake was found after gene transfer, using a systems, region-of-interest analysis ( Fig. 3.4 ) [ 117 ] . These fi ndings counter the typical AD pattern of loss of 18-Fluorodeoxyglucose uptake over time, although the sample size is too small to draw defi nitive conclusions.
Postmortem pathological analysis was performed in all subjects in the fi rst phase 1 trial, up to 10 years after gene transfer [ 119 ] . All subjects at the time of death had advanced Braak stage V-VI Alzheimer's disease. Surviving fi broblasts were observed in all cases in the region of NGF gene transfer. Most notably, every brain exhibited evidence of a trophic response to NGF, refl ected by cholinergic axon sprouting into the fi broblast graft ( Fig. 3.5 ). These fi ndings indicate that degenerating neurons in the AD brain are consistently able to exhibit a classic "trophic" (sprouting) response to NGF. Sub-analysis of brains in subjects who underwent unilateral gene transfer demonstrated cell hypertrophy of ~8 % on the treated side ( P < 0.05), another trophic response.
In summary, the fi rst Phase 1 clinical trial of ex vivo NGF gene therapy in AD supported the rationale of providing trophic support to cholinergic neurons, a program that has been expanded into a phase 2 program.
NGF Gene Therapy: Phase 1 and 2 In Vivo Clinical Trials
The NGF ex vivo gene therapy clinical program began before in vivo gene therapy vectors were widely available for clinical use. However, by the completion of the Phase 1 ex vivo trial, experience with adeno-associated virus (AAV) vectors had advanced considerably. Clinical trials with in vivo gene therapy vectors offered substantial potential advantages. In ex vivo gene therapy trials, patient fi broblasts were biopsied, expanded, transduced to express the gene of interest, tested, harvested, and shipped to a physician for intracranial injection. In vivo gene therapy is substantially simpler: the AAV vector product can be processed in large batches, characterized, tested, and sent to a physician for injection. Moreover, in preclinical studies, AAV2-NGF gene delivery was as safe and effective compared as ex vivo gene therapy [ 120 ] . In addition, the duration of in vivo gene expression was superior when using AAV2 vectors [ 121 ] . For these reasons, a decision was made to switch NGF program development from ex vivo gene therapy using grafts of autologous fi broblasts to in vivo gene therapy using AAV2-NGF vectors. Several other clinical trials also utilized AAV gene therapy in the nervous system [ 122 -125 ] (see Chaps. 2 , 4 , 5 , and 7 ). Preclinical studies using AAV-NGF gene delivery supported the transition to clinical trials. AAV2-NGF gene therapy ameliorated age-related defi cits in spatial memory and resulted in increases in cholinergic cell size in aged rats [ 126 ] . AAV2-NGF was also shown to be neuroprotective in the brains of aged rats and to sustain gene expression over time [ 120 ] . Another in vivo gene therapy vector, lentivirus (expressing NGF), also prevented the death of cholinergic forebrain neurons following fi mbria fornix lesions in rats [ 127 ] . In the primate brain, Lenti-NGF resulted in long-term in vivo NGF expression and reversed age-related declines in the number and size of basal forebrain cholinergic neurons [ 128 ] .
Supported by these preclinical data, a company-sponsored Phase 1 clinical trial of AAV2-NGF was initiated in nine patients. Subjects had mild to moderate AD (mini-mental status exam scores of 16-28) [ 129 ] . AAV2-NGF was stereotaxically injected in the nucleus basalis region at one of three doses. All AAV2-NGF doses were found to be safe and well tolerated, and this program progressed to initiation of a Phase 2 multicenter trial primarily funded by the National Institutes for Aging in 2011.
We received brains from two patients who received AAV2-NGF in the preceding clinical trial (Fig. 3.6 ). NGF was persistently expressed by cells in the nucleus basalis of Meynert at 11 months and 3 years posttreatment, respectively ( Fig. 3.6 ). NGF appeared to induce cholinergic neuronal hypertrophy, and in both subjects appeared to increase expression of the immediate early gene c-fos in the zone of NGF expression.
The phase 2 trial of AAV2-NGF gene delivery in AD is designed to extend the safety and tolerability data of AAV2-NGF gene delivery program in AD, and to determine the potential effect size of AAV2-NGF in AD patients. The trial is a double-blind design, and includes a sham surgery control group. A total of 49 patients are enrolled at 1 of 11 clinical centers across the United States [ 130 ] . Approximately half of patients receive the highest AAV2-NGF "dose" of the phase 1 trial (2 × 10 11 viral genomes per brain). The other half of patients undergo sham surgery that involves drilling a partial burr hole, without penetrating the dura. The primary endpoint is change in the Alzheimer's Disease Assessment Scale-Cognitive subcomponent (ADAS-Cog) over a 2-year follow-up period. Several secondary endpoints are also being measured, sampling several cognitive realms. This Phase 2 trial is underpowered to yield a statistically signifi cant determination of AAV2-NGF treatment on cognitive function, but it is expected to provide an estimate of the potential "effect size" of AAV2 NGF, allowing a "go" versus "no-go" decision for this clinical program, using its current gene delivery methods (see below). If a suffi cient potential effi cacy signal is detected, then an adequately powered subsequent effi cacy trial will be designed.
A challenge that has become evident in histopathological analysis of brains of patients treated in the Phase 1 ex vivo and Phase 1 in vivo NGF therapy trials is the accuracy of neurosurgical targeting of deep brain structures with vector delivery. [ 173 ] At the AAV2 vector concentrations and volumes that have been administered in these clinical programs, NGF spread from the injection site is generally less than 2 mm. In several brains identifi ed to date, NGF expression may not have reached the targeted cholinergic neurons, a caveat that will need to be considered in interpreting the outcomes of the Phase 2 AAV2-NGF trial. Improved methods of vector targeting may be needed. Such methods are being integrated into the AAV2-BDNF program in AD described below, including real-time MR imaging of vector administration and convection-enhanced delivery of larger vector volumes to enhance vector spread.
The Phase 1 clinical trial of ex vivo gene therapy began 14 years ago. With results of the Phase 2 trial expected soon, the program is at a pivotal point. One might refl ect back on the long length of time it has taken to come to this point. The slow pace of progression of this program likely is due to several factors: (1) caution of the gene therapy clinical trial realm when the program was initiated in the early 2000s, and some continued caution today; (2) the challenges of funding an earlystage clinical program that breaks new ground using novel technologies; and (3) the diffi culty of conducting clinical trials in complex neurodegenerative disorders that largely lack robust clinical measures and effi cacy end points. These challenges are not unique to the fi eld of gene therapy or to Alzheimer's disease.
BDNF Gene Therapy for Alzheimer's Disease
Rationale
BDNF is another neurotrophic factor with substantial potential to reduce neuronal degeneration and stimulate neuronal function in cell systems that degenerate in AD. BDNF, like NGF, supports neuronal survival, axonal outgrowth, and appropriate target innervation during neural development. In contrast to NGF, which infl uences cholinergic neurons of the basal forebrain, BDNF directly infl uences the survival and function of cortical and hippocampal neurons [ 131 , 132 ] . Neurons of the cortex and hippocampus are central to the development of cardinal symptoms of AD, and these same neurons express the BDNF receptor, trkB [ 131 , 132 ] . In the NGF gene therapy program, NGF could prevent or slow the loss of cholinergic neurons of the basal forebrain, thereby improving symptoms in early and middle stages of the disease. However, NGF does not directly support neurons of the cortex and hippocampus, and these neurons would eventually degenerate even if NGF were successful in preserving cholinergic systems. In contrast, BDNF gene therapy could in theory directly preserve or prolong the survival of key hippocampal and cortical circuitry that degenerates in AD, providing a more potent or sustained effect.
During life, BDNF functions as an important molecule in normal brain function. BDNF infl uences gene expression, and, at the level of synapses, vesicular clustering and docking, neurotransmitter release, and long-term potentiation [ 133 , 134 ] .
A key focus of the BDNF gene therapy program in AD is the entorhinal cortex. This medial temporal lobe structure exerts a critical role in new memory formation [ 135 ] . Diverse brain regions project into the entorhinal cortex, which acts as a relay to hippocampal circuitry. The hippocampus then projects back to the entorhinal cortex, which in turn projects to the diverse cortical regions that represent storage sites of many types of memories. Collectively, new memory formation requires essential cellular and electrophysiolgical "plastic" mechanisms contained within hippocampal and entorhinal circuits.
Notably, one of the earliest brain regions affected by AD pathology is the entorhinal cortex [ 19 , 38 , 40 ] . A direct consequence of degeneration of entorhinal-hippocampal circuits is the earliest and cardinal clinical symptom of AD, short-term memory loss [ 14 , 16 ] . The spread of neuropathology in AD may refl ect anatomical connections of other brain regions with the entorhinal cortex, as a consequence of either spreading beta amyloid [ 20 , 43 , 44 ] or Tau [ 45 , 46 ] pathology. Signifi cantly, levels of BDNF decline in the entorhinal cortex in the earliest stages of AD [ 28 , 30 , 106 ] . Thus, it is hypothetically possible that specifi c targeting of BDNF to entorhinal circuitry could dampen early pathogenesis in AD, thereby delaying progression of short-term memory loss. If disease pathologically is directly propagated from the entorhinal cortex to other brain regions, it is also possible that BDNF-mediated neuroprotection in the entorhinal cortex could delay disease progression to other brain regions. Accordingly, in preclinical models of AD we investigated whether BDNF gene therapy to entorhinal circuitry prevented neuronal degeneration and stimulated neuronal function [ 75 , 136 ] .
Preclinical Studies of BDNF Gene Therapy
We examined six models of AD to determine whether BDNF exerted neuroprotective effects in entorhinal/hippocampal circuitry [ 75 ] . Transgenic mice that overexpress known human mutations in the amyloid precursor protein (APP) gene are one of the most broadly studied models of AD [ 137 ] . Humans bearing these mutations suffer a premature onset of AD. We injected lentiviral vectors expressing BDNF into the entorhinal cortices of APP transgenic mice at 6 months of age, after disease onset; mice express characteristic plaque deposition and the beginning of neuronal loss prior to this age [ 75 , 136 ] . The BDNF gene was expressed in the entorhinal cortex, but the locally produced BDNF protein spread by anterograde transport down axons and into the hippocampus (Fig. 3.7a ). BDNF protein in the entorhinal cortex and hippocampus was associated with a reversal of loss of the presynaptic protein synaptophysin. BDNF gene delivery also activated neuronal ERK, an important cell signaling molecule related to functional state of neuronal activation. Transcriptome analysis showed that BDNF treatment reversed two-thirds of APPinduced disruptions in global gene expression caused by the APP mutation ( Fig. 3.7b ). Moreover, APP-transgenic mice treated with BDNF exhibited improvement on two cognitive measures of hippocampal-dependent learning and memory:
the Morris water maze and contextual fear conditioning ( Fig. 3.7c, d ) . However, BDNF gene delivery had no effect on amyloid plaque deposition, suggesting that benefi cial effects of BDNF gene delivery were independent of reductions in amyloid plaque density in the brain. Instead, BDNF appeared to exert direct effects on neuronal survival, synaptic proteins, and gene expression.
More recently, we initiated treatment with BDNF at an earlier time point in APP transgenic mice, before disease onset [ 136 ] . The purpose of this study was to determine whether BDNF treatment could prevent neuronal loss in the entorhinal cortex that proceeds over several months in APP transgenic rats. Indeed, when treatment was initiated at 2-3 months of age, neuronal loss was signifi cantly reduced when examined at 7 months of age. In addition, early life BDNF gene delivery produced a signifi cant improvement in learning and memory, and an increase in the presynaptic protein synaptophysin in the entorhinal cortex and hippocampus [ 136 ] . Once again, BDNF did not affect amyloid plaque load, suggesting that BDNF acts through mechanisms independent of amyloid.
Another model of AD, albeit imperfect, is normal aging. Aging is a major risk factor for the development of AD, and aging is associated with neuronal atrophy and declines in several functional cellular markers. We infused recombinant BDNF protein into entorhinal cortices of aged Fischer 344 rats. When examined 2 months later, we found that BDNF infusions ameliorated age-related declines in spatial memory, restored levels of ERK phosphorylation to levels of young animals, and reversed age-related perturbations in gene expression [ 75 ] .
We then extended these studies to nonhuman primates. Aged rhesus monkeys were tested for baseline function on a computerized memory task and then underwent lentiviral BDNF gene delivery to bilateral entorhinal cortices. We found that BDNF gene delivery ameliorated age-related impairments in short-term memory, and subsequent anatomical analysis showed induction of entorhinal neuronal hypertrophy. Thus, BDNF gene delivery to the entorhinal cortex of nonhuman primates exhibited signifi cant effects on cognition and cell morphology [ 136 ] .
We also examined whether BDNF gene delivery to the entorhinal cortex could prevent another mechanism of cell dysfunction: axotomy-induced neuronal degeneration [ 136 ] . Rats underwent perforant pathway lesions that sever axonal projections from the entorhinal cortex to the hippocampus. In lesioned subjects lacking BDNF treatment, a signifi cant loss of neurons occurred in layer II of the entorhinal cortex. In contrast, animals that received BDNF gene delivery showed signifi cant reductions in cell death [ 75 ] . Extending these fi ndings once again to a nonhuman primate model, we found that perforant pathway lesions in adult monkeys caused nearly 50 % loss of neurons in layer II of the lateral entorhinal cortex and that BDNF gene delivery rescued the majority of these cells from death [ 75 ] (Fig. 3.8a, b ) . Thus, BDNF demonstrated neuroprotection across species, animal models, and mechanisms of experimental neurodegeneration. Collectively, the preceding studies support the hypothesis that BDNF can promote neuronal survival and augment the functional state of neurons in correlative models of AD. These fi ndings are supported by other studies. Another group demonstrated that BDNF gene delivery into the brains of APP transgenic mice also improved synapatic markers and memory performance, without directly affecting beta amyloid [ 70 ] . In separate studies, gene delivery of a binding protein for CREB (cAMP-response element binding protein) increased BDNF expression and improved memory defi cits in an AD mouse model [ 138 ] . Furthermore, neural stem cells secrete BDNF, and transplantation of neural stem cells in a transgenic mouse model of AD improved synaptic markers and improved memory; these improvements were not observed when BDNF expression was blocked in the transplanted cells [ 137 ] .
Given the preceding body of evidence across disease models and laboratories, we propose to develop AAV2-BDNF gene therapy for clinical trials. Like NGF, broad distribution of BDNF in the central nervous system has the potential to generate off-target effects that could be disabling. Nervous system growth factors must be administered to regions of neurodegeneration without spread to non-degenerating regions to avoid these potential adverse effects. Two potential paths present themselves for this clinical program: gene therapy or intraparenchymal protein infusion. Given the relative simplicity of gene delivery and its track record of safety in hundreds of patients enrolled across several trials [ 117 , 122 -124 , 140 -142 ] , we are focusing for the present on gene delivery.
Improved Tools for Gene Delivery to the Brain: Real-Time Imaging and Convection Enhanced Delivery of AAV2-BDNF in AD
Targeting deep structures for gene delivery in the human brain is a challenge. Stereotaxic neurosurgical procedures have a resolution in experienced hands of 1-2 mm in accurately reaching their target, but this may not be suffi ciently accurate when targeting a structure like the nucleus basalis of Meynert in the NGF program, or the entorhinal cortex in the BDNF program. For example, the thickness of the human entorhinal cortex from cortical surface to subcortical white matter is approximately 3 mm [ 143 , 144 ] , and the preferred target is layer II-III of the entorhinal cortex, which is ~1 mm thick. Ideally, a method would be available in which (1) a catheter for gene therapy vector infusion into the brain can be imaged in real time and the accuracy of its position confi rmed, and (2) spread of vector through the intended targeted brain region can be confi rmed in real time. These methods have recently been developed by Bankiewicz and colleagues [ 145 -148 ] . Using MRIcompatible ceramic infusion needles and co-infusion of gene therapy vector with a radiological tracer (gadoteridol), they report an ability to accurately target AAV vector delivery to brain structures [ 149 , 150 ] . The addition of convection-enhanced delivery techniques can further optimize vector distribution in a desired brain target region [ 150 , 151 ] . Convection-enhanced delivery is an infusion technique wherein continuous fl ow rates that exceed intraparenychmal hydrostatic pressure (0.5 μl/min for the brain) result in a "push" of fl uid more extensively through the brain (Fig. 3.9 ). These technological developments could represent a major breakthrough for targeting and distribution of gene therapy vectors in human neurological disorders. Previous "blind" methods of gene delivery using standard stereotaxic infusions have resulted in vector distribution more limited in distribution than had been modeled in preclinical studies [ 152 ] , highlighting the need for improvements in delivery technology. We have developed these procedures to target the entorhinal cortex in nonhuman primates ( Fig. 3.9 ), and will implement this technology in clinical trials of AAV2-BDNF in AD.
Gene Therapy in AD: Delivery of Other Therapeutic Genes
Alterations in amyloid processing and deposition represent a major target in AD drug development. Several studies have used techniques of gene therapy to target beta amyloid in animal models of AD, as described below [ 66 , 67 , 74 , 78 , 81 , 153 ] . Gene therapy methods have also been employed to target other AD-related mechanisms, including tau and neuroinfl ammation.
Gene Therapy and Amyloid Degradation
Gene therapy has been used in preclinical studies to degrade amyloid in mice overexpressing human amyloid mutations. For example, overexpression of the enzymes neprilysin (NEP), insulin-degrading enzyme (IDE), or endothelin-converting enzyme (ECE) can modify amyloid accumulation in the brains of transgenic mice. Neprilysin, a natural brain enzyme, is a membrane-bound metalloprotease that degrades several small peptides including beta amyloid [ 154 ] . In AD, levels of Neprilysin mRNA and protein are reduced [ 155 , 156 ] . When experimentally overexpressed in the brain of APP transgenic mice, neprilysin, insulin-degrading enzyme, or endothelin-converting enzyme all reduce amyloid plaque formation [ 64 , 78 , 157 , 158 ] . Masliah and colleagues also reported that systemic delivery of a gene therapy vector could achieve reduction in brain amyloid [ 159 ] . They used a lentiviral vector expressing neprilysin fused with Apoliproprotein B (ApoB), a low-density lipoprotein receptor-binding domain that is able to cross the blood-brain barrier. When administered to APP transgenic mice, neprilysin crossed the blood-brain barrier and reportedly improved synaptic density and memory performance [ 159 ] . An independent study also reported that invascular injection AAV9-Neprilysin elevated neprilysin activity in the brain and reduced amyloid oligomers [ 160 ] . Thus, gene therapy to express enzymes that degrade beta amyloid represents a potential therapy for AD.
As summarized above, a number of AD clinical trials attempt to autoimmunize patients against beta amyloid to enhance its clearance. Gene therapy has been reported as an alternative means of expressing peptide fragments in the brain that could result in immunization. For example, AAV viral vectors encoding synthetic beta amyloid fragments result in production of amyloid antibodies in a mouse model of AD when combined with an adjuvant (granulocyte/macrophage-colony stimulating factor) [ 161 ] . Amyloid antibodies were formed and the density of plaques was reduced in transgenic mice [ 66 , 162 ] .
RNA Interference in AD
Gene therapy can also be used to produce small interfering RNAs (siRNAs) in the brain. For the treatment of AD, siRNAs that suppress beta or gamma secretase expression could reduce amyloid precursor protein cleavage at sites leading to beta amyloid production. In one study, lentiviral vectors expressing siRNAs to beta secretase and infused into the hippocampus signifi cantly reduced amyloid deposition and improved cognitive in APP transgenic mice [ 153 ] . Gene delivery of siR-NAs directed against presenilin 1, a protein that elevates beta amyloid levels, can also reduce beta amyloid in mouse models of AD [ 163 ] . RNA interference has also been directed against tau, using siRNAs that reduce levels of GSK-3 and CDK5 to reduce tau phosphorylation [ 76 , 164 ] .
Other Gene Therapy in AD
AAV-mediated gene delivery of interleukin-10 (IL-10) or interleukin-4 (IL-4) appears to reduce astrogliosis and microglial activation, resulting in reduced amyloid accumulation in amyloid mutant mice [ 72 , 165 ] . Overexpression of a CREB binding protein in mice expressing mutant amyloid increased BDNF protein levels and improved memory, as noted above [ 138 ] . Other gene delivery studies have also reported therapeutic effects in animal models of AD [ 76 , 166 , 168 ] . Thus, a broad range of possibilities for future gene-based therapy of AD exist.
Future Gene Therapy for AD
A key to the future development of gene therapy for any indication, including AD, is the ability to regulate the expression of viral vector products [ 127 , 168 ] . This is especially important when a candidate gene delivery product could have adverse consequences, as in off-target effects of neurotrophic factors. While more than 200 humans treated in AD and Parkinson's disease programs to date have shown no evidence of off-target effects from trophic factor overexpression, regulatable expression or incorporation of a suicide gene in the expression vector would enhance the safety profi le of gene therapy. Another active focus of development in the gene therapy fi eld is the design of novel vectors, hybrid vectors, and cell-specifi c promoters that enhance neuron or glia-specifi c gene expression, movement across the blood-brain barrier, and retrograde vector transport [ 169 -172 ] (see Chap. 2 ).
Summary
Gene delivery is an intriguing tool for the potential therapy of AD and other disorders. It solves the problem of achieving regionally specifi c delivery of large proteins into the brain. Modern vectors sustain gene expression over prolonged time periods-years-after a single vector administration procedure, providing the possibility for prolonged in vivo effi cacy and eliminating the need for daily drug ingestion. Yet a breakthrough has not yet come, and carefully designed and conducted clinical trials remain necessary to ultimately prove the value of this technology for human disease treatment. Promising possibilities from the fi eld of nervous system disorders, ocular diseases, inborn errors of metabolism, or cancer could provide this breakthrough. 
